News

Calix, Inc. released its Q2 2026 earnings on July 20, reporting revenue of $293.3 million—up 21 % year‑over‑year and 5 % sequentially. Appliance revenue climbed to $242.8 million from $198.1 million, while software and services generated a record $50.5 million. GAAP net income reached $17.1 million ($0.26 EPS), beating the Zacks consensus by $0.07 ...

Full article

TEM plans to provide further detail on the transaction’s financial impact during its second‑quarter earnings call on July 30, as it works toward a positive adjusted EBITDA and free‑cash‑flow outlook in 2027 while leveraging the expanding demand for precision oncology and MRD testing.

Full article

Investor reaction to the announcement was negative: TEM shares fell as much as 9.2 % to $47.65 in early trading, while Personalis shares declined up to 15 %. TEM’s market cap of $8.69 billion would increase to roughly $10.2 billion upon completion, reflecting the combined value of Personalis’ $1.4 billion market cap. Analysts highlighted the long c...

Full article

The acquisition is aimed at bolstering TEM’s minimal residual disease (MRD) testing capabilities. TEM notes that its MRD offering has seen a 38 % quarter‑over‑quarter growth and that embedding additional AI‑enabled ordering tools and hospital connectivity will further enhance the platform. Personalis’ NeXT Personal assay has secured Medicare covera...

Full article

On the strategic front, TEM announced a planned acquisition of Personalis (NASDAQ:PSNL) in a 100 % stock transaction valuing Personalis at $1.5 billion net of TEM’s existing ownership, with an offer price of $16.25 per share—representing a 6 % premium to the Friday close and a 28 % premium to the 30‑day VWAP. The deal is expected to close in late 2...

Full article

Tempus AI (NASDAQ:TEM) has experienced a 22.4 % year‑to‑date decline, trading at a price‑to‑sales ratio of 6.4x—below the sector‑adjusted fair value of approximately 7.9x—while remaining unprofitable and under cash‑flow pressure. The company’s latest clinical traction is centered on its Paige Prostate AI platform, which has begun deployment in real...

Full article

For capital markets, the deal signals a significant consolidation in the precision oncology space, potentially influencing valuations of MRD‑focused companies and reinforcing the trend toward AI‑enabled, data‑driven oncology platforms. The integration is expected to accelerate growth for both firms and provide expanded access to a high‑growth, Medi...

Full article

Julie & Holleman LLP has raised concerns that Tempus’s pre‑existing ownership and strategic relationship may have created conflicts of interest, questioning whether public shareholders are receiving fair value for their shares. The firm is investigating whether the $16.25 per‑share price reflects Personalis’s true worth, especially given the market...

Full article

The deal follows a strategic partnership formed in 2023, in which Tempus already held a significant equity stake in Personalis. Tempus CEO Eric Lefkofsky stated that the transaction positions both companies “collectively well positioned to capture this opportunity,” while Personalis CEO Chris Hall highlighted that the acquisition provides the scale...

Full article

Personalis brings its flagship NeXT Personal test, an MRD‑based assay that detects circulating tumor DNA to monitor cancer recurrence. The test already has Medicare coverage in three indications and sits within a rapidly expanding market that the two companies value at $20 billion. By integrating Personalis’s ultrasensitive MRD technology with Temp...

Full article